A first in human study of BAY 1834942.

Trial Profile

A first in human study of BAY 1834942.

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs BAY 1834942 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 11 Apr 2018 New trial record
    • 05 Apr 2018 According to a Bayer media release, company is planning to start this study in 2018. Bayer is developing this drug in collaboration with German Cancer Research Center (DKFZ).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top